You are here

Nano-Antibodies for Studying RNA Modifications

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43DA038978-01
Agency Tracking Number: R43DA038978
Amount: $225,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: NIDA
Solicitation Number: DA15-001
Timeline
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
9924 Mesa Rim Road
SAN DIEGO, CA 92121-2910
United States
DUNS: 21345447
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 JIWU WANG
 (858) 587-6645
 jiwuwang@allelebiotech.com
Business Contact
 JIWU WANG
Phone: (858) 587-6645
Email: jiwuwang@allelebiotech.com
Research Institution
 Stub
Abstract

DESCRIPTION (provided by applicant): The goal of the proposed Phase I research is to develop a set of commercial reagents for recognizing 2'-O-methyladenosine (Am), 2'-O-methylcytidine (Cm), 2'-O-methylguanosine (Gm) or 2'-O-methyluridine (Um), as well asindiscriminately to all four 2'-O-methyl ribose moiety. The core technologies that serve as the foundation of these new reagents are based on the unique properties of camelid antibodies, which have been well accepted as valuable binding reagents for proteins and haptens, but so far without any example for RNA modifications. The main advantage of the proposed single-domain (VHH) antibodies from camelidae is that they have very high affinity and specificity, and they are easy to reproduce as monoclonal antibodies, stable, and of very small size, enabling super-resolution imaging when conjugated to dye. Currently, affinity reagents of any type are only available for monitoring a handful among the more than 100 RNA modification moieties. The best examples o

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government